Your browser doesn't support javascript.
loading
Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade.
Berry, Sneha; Giraldo, Nicolas A; Green, Benjamin F; Cottrell, Tricia R; Stein, Julie E; Engle, Elizabeth L; Xu, Haiying; Ogurtsova, Aleksandra; Roberts, Charles; Wang, Daphne; Nguyen, Peter; Zhu, Qingfeng; Soto-Diaz, Sigfredo; Loyola, Jose; Sander, Inbal B; Wong, Pok Fai; Jessel, Shlomit; Doyle, Joshua; Signer, Danielle; Wilton, Richard; Roskes, Jeffrey S; Eminizer, Margaret; Park, Seyoun; Sunshine, Joel C; Jaffee, Elizabeth M; Baras, Alexander; De Marzo, Angelo M; Topalian, Suzanne L; Kluger, Harriet; Cope, Leslie; Lipson, Evan J; Danilova, Ludmila; Anders, Robert A; Rimm, David L; Pardoll, Drew M; Szalay, Alexander S; Taube, Janis M.
Afiliação
  • Berry S; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.
  • Giraldo NA; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.
  • Green BF; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Cottrell TR; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Stein JE; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.
  • Engle EL; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.
  • Xu H; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Ogurtsova A; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Roberts C; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Wang D; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.
  • Nguyen P; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.
  • Zhu Q; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Soto-Diaz S; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.
  • Loyola J; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.
  • Sander IB; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Wong PF; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.
  • Jessel S; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.
  • Doyle J; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Signer D; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.
  • Wilton R; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Roskes JS; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Eminizer M; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Park S; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Sunshine JC; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.
  • Jaffee EM; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Baras A; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.
  • De Marzo AM; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Topalian SL; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Kluger H; Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.
  • Cope L; Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.
  • Lipson EJ; Department of Astronomy and Physics, Johns Hopkins University, Baltimore, MD 21218, USA.
  • Danilova L; Institute for Data Intensive Engineering and Science, Johns Hopkins University, Baltimore, MD 21218, USA.
  • Anders RA; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Rimm DL; Department of Astronomy and Physics, Johns Hopkins University, Baltimore, MD 21218, USA.
  • Pardoll DM; Institute for Data Intensive Engineering and Science, Johns Hopkins University, Baltimore, MD 21218, USA.
  • Szalay AS; Department of Astronomy and Physics, Johns Hopkins University, Baltimore, MD 21218, USA.
  • Taube JM; Institute for Data Intensive Engineering and Science, Johns Hopkins University, Baltimore, MD 21218, USA.
Science ; 372(6547)2021 06 11.
Article em En | MEDLINE | ID: mdl-34112666
Next-generation tissue-based biomarkers for immunotherapy will likely include the simultaneous analysis of multiple cell types and their spatial interactions, as well as distinct expression patterns of immunoregulatory molecules. Here, we introduce a comprehensive platform for multispectral imaging and mapping of multiple parameters in tumor tissue sections with high-fidelity single-cell resolution. Image analysis and data handling components were drawn from the field of astronomy. Using this "AstroPath" whole-slide platform and only six markers, we identified key features in pretreatment melanoma specimens that predicted response to anti-programmed cell death-1 (PD-1)-based therapy, including CD163+PD-L1- myeloid cells and CD8+FoxP3+PD-1low/mid T cells. These features were combined to stratify long-term survival after anti-PD-1 blockade. This signature was validated in an independent cohort of patients with melanoma from a different institution.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / Imunofluorescência / Receptor de Morte Celular Programada 1 / Antineoplásicos Imunológicos / Melanoma Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Science Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / Imunofluorescência / Receptor de Morte Celular Programada 1 / Antineoplásicos Imunológicos / Melanoma Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Science Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos